Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

The panel of start-up executives, directors, and investors will discuss their perspectives on how to crystalize and close subsequent-stage investment rounds, a complex and unclear path from the outside, but a vital step in the process for founders, while navigating the many personalities and interests involved.

View from the Board—Navigating New Funding Rounds with Current VC Directors

When raising a seed round of venture capital, the focus of founders tends toward securing meetings and “acing” their pitches. It is a critical moment in the growth of an early-stage biotech that the first interested party is secured in order to more easily convince other investors to join and complete that round of funding. But what happens when you do succeed in generating interest and commitments for your initial round, and the focus shifts to fundraising new funding rounds? CEOs must then walk the fine line during discussions with the current board regarding new investor capital contributions, dilution rights, criteria for new board members, and the overall, long-term health of the company. The panel of start-up executives, directors, and investors will discuss their perspectives on how to crystalize and close subsequent-stage investment rounds, a complex and unclear path from the outside, but a vital step in the process for founders, while navigating the many personalities and interests involved.Moderator: Michael J. O’Donnell, Partner, Morrison & Foerster LLPPanelists:<ul><li>Rajeev Dadoo, PhD, Partner, S.R. One</li><li>David H. Donabedian, PhD, Chief Executive Officer, Axial Biotherapeutics; Partner, Longwood Fund</li><li>Julie Papanek Grant, Partner, Canaan Partners</li><li>Julia C. Owens, PhD, President & CEO, Millendo Therapeutics, Inc.</li><li>Camille Samuels, Partner, Venrock</li></ul><hr>

View from the Board—Navigating New Funding Rounds with Current VC Directors

Sign Up

View from the Board—Navigating New Funding Rounds with Current VC Directors - 448324103

View from the Board—Navigating New Funding Rounds with Current VC Directors

17 Oct 2017 10:15 PM - 11:10 PM